The composition containing an effective amount of diamide compound and the method for treating or preventing liver fibrosis disorder or disease can be treated or prevented by inhibiting JNK. Requirement 1: a compound (1) with formula characteristics.and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, and prodrugs thereof, wherein: R1 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl unscented, substituted or unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkylheterocyclyl, provided that R1 is not 1-aminocyclohexyl； R2 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted saturated cycloalkyl, substituted or unsubstituted alkylcycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl；As long as the compound is not 2 - (2-aminoethylamine) - 4 - (methylamine) pyridine-5-aminomethylamine, 2 - (2-aminopropene) - 4 - (cyclohexane) pyridine-5-aminomethylamine, 2 - (2-amino-2-oxoetilamine) - 4 - (cyclohexane) pyridine-5-sulfanilamide, 2 - (2-aminoacetamide) - 4 - (cyclohexane) pyridine-5 Amin pilboxyl pilboxyl pilboxyl pilboxyprinda). Claim 34: a compound (2) having formula properties,and pharmaceutically acceptable salts, tautomers, stereoisomers, enantiomers, isotopologists and prodrugs thereof, wherein: R3 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted non-aromatic heterocyclyl, substituted or unsubstituted alkylcycloalkyl, or substituted or unsubstituted alkyl- (heterocycloalkyl)； R4 is substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted unsaturated heterocyclyl； provided that the compound is not 4- (isopentylamino) -2- (3- (2-methylpiperidin-1-yl) propylamino) pyrimidin-5-carbonitrile；2,2 '- (5-cyanopropyl-2,4-diil) bis (azandil) bis (4-methyl pentanoato) de (2S, 2's) - dimetry； 2,2' - (5-cyanoprop
